Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 0.67 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | GSK3B | P49841 | 3/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247759 | 1.00 | PIM1 (0.67) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL1250569 | 0.87 | NAT1 (0.66) | RAB9AMAOANPC1CISD1 | |
| SCHEMBL1250567 | 0.87 | NAT1 (0.66) | RAB9AMAOANPC1CISD1 | |
| SCHEMBL8003882 | 0.82 | HPGD (0.72) | PIM1PIM2HPGDMAOAMAOB | |
| SCHEMBL2547566 | 0.80 | PIM1 (1.00) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL2545594 | 0.80 | PIM1 (1.00) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL2545596 | 0.80 | PIM1 (1.00) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL211085 | 0.78 | PIM1 (1.00) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL1125013 | 0.78 | PIM1 (0.72) | PIM1PIM2HPGDPIM3GSK3B | |
| SCHEMBL4862901 | 0.78 | PIM1 (0.72) | PIM1PIM2HPGDPIM3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| US-20060258561-A1 | Novel NPH insulin preparations | NOVO NORDISK A/S (DK) | 2006-11-16 | — | — | US | disclosed |
| WO-2006082245-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING INSULIN, ZINC IONS AND A ZINC-BINDING LIGAND | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | NOVO NORDISK A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002062337-A1 | THIAZOLIDINEDIONES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258561-A1 | Novel NPH insulin preparations | IAPP, HBB, INSR | PIM1 3313/4885PIM2 3745/4885HPGD 3521/4885 |
| US-20060069013-A1 | Pharmaceutical preparations comprising acid-stabilised insulin | IAPP, GPR119, INSR | PIM1 4279/4885PIM2 4562/4885HPGD 2233/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | PIM1 4412/4885PIM2 4504/4885HPGD 3173/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | PIM1 3653/4885PIM2 4144/4885HPGD 4068/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PIM1 3773/4885PIM2 4301/4885HPGD 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.